Advanced search×
×

Clinical Therapeutics

Print ISSN
0149-2918
Electronic ISSN
1879-114X
Impact factor
2.551
Publisher
Sciencedirect
URL
http://www.sciencedirect.com/science/journal/01492918
Usage rank
431
Article count
4656
Free count
20
Free percentage
0.00429553
PDFs via platforms
Gale, Ingenta, Rcgp, and Sciencedirect from 1995

  1. Reviewing a Clinical Decision Aid for the Selection of Anticoagulation Treatment in Patients With Nonvalvular Atrial Fibrillation: Applicati...

    Clinical Therapeutics 36(11):1566 (2014)

    We describe theoretical implications of utilizing the aid at a US managed care population level....
  2. Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study.

    Clinical Therapeutics 36(9):1255 (2014) PMID 25082730

    Long-acting insulin analogues were developed to facilitate consistent glycemic control without excessive hypoglycemia. However, structural modifications of the insulin molecule can alter biological responses and binding characteristics with specific receptors. The aim of this study was to estimate t...
  3. Three-year cost-effectiveness model for non-animal stabilized hyaluronic acid and dextranomer copolymer compared with sacral nerve stimulati...

    Clinical Therapeutics 36(6):890 (2014) PMID 24815061

    Two new therapies for fecal incontinence (FI) are now available: non-animal stabilized hyaluronic acid and dextranomer copolymer (NASHA/Dx) and sacral nerve stimulation (SNS). This study aimed to determine the cost-effectiveness of NASHA/Dx compared with SNS and conservative therapy (CT) for the tre...
  4. Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells.

    Clinical Therapeutics 36(6):847 (2014) PMID 24952935

    Exosomes are small (30- to 100-nm) vesicles secreted by all cell types in culture and found in most body fluids. A mean of 1 mL of blood serum, derived from healthy donors, contains approximately 10(12) exosomes. Depending on the disease, the number of exosomes can fluctuate. Concentration of exosom...
  5. Effect of Ketoconazole on the Pharmacokinetics of the Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: An Open-Label Study in Healthy White S...

    Clinical Therapeutics 36(5):760 (2014) PMID 24726088

    Objective The aim of this study was to examine the effect of ketoconazole, a potent cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp) inhibitor, on teneligliptin pharmacokinetics and to evaluate the safety of combined administration of teneligliptin with ketoconazole....
  6. Analysis of Chemotherapy Dosage and Dosage Intensity and Survival Outcomes of High-Grade Osteosarcoma Patients Younger Than 40 Years

    Clinical Therapeutics 36(4):567 (2014) PMID 24636527

    Background Chemotherapy is essential for long-term survival of osteosarcoma patients. However, the impact of dosage and dosage intensity (DI) of chemotherapeutic agents on patients with high-grade osteosarcoma is largely unknown.
  7. Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.

    Clinical Therapeutics 36(1):58 (2014) PMID 24417785

    Now that generic atorvastatin has become available, a process of switching from rosuvastatin to atorvastatin may occur and could persist until the patent on branded rosuvastatin expires. It is important to understand the impact that such therapy may have on patients' cardiovascular (CV) health. This...
  8. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide...

    Clinical Therapeutics 35(8):1162 (2013) PMID 23911260

    LX4211 is a first-in-class dual inhibitor of sodium-dependent glucose cotransporters 1 and 2 (SGLT1 and SGLT2). SGLT1 is the primary transporter for glucose absorption from the gastrointestinal tract, and SGLT2 is the primary transporter for glucose reabsorption in the kidney. SGLT1 inhibition reduc...
  9. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.

    Clinical Therapeutics 35(7):1005 (2013) PMID 23831360

    We selected patients who were being treated following the therapeutic recommendations of the National Osteoporosis Foundation or the guideline for glucocorticoid-induced osteoporosis recommended by the American College of Rheumatology. Adherence was determined by compliance and the persistence ratio...
  10. Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/h...

    Clinical Therapeutics 35(5):673 (2013) PMID 23587606

    Attention deficit/hyperactivity disorder (ADHD) is a heterogeneous behavioral disorder commonly found in children, with serious lifetime health and social consequences for both children and their parents. Public awareness of ADHD in Germany has increased in the past decade, but little is known about...